Stockscreener 앱 받기
3.55
2.90%
0.10
시간 외 거래:
3.38
-0.17
-4.79%
전일 마감가:
$3.45
열려 있는:
$3.55
하루 거래량:
60,302
Relative Volume:
1.49
시가총액:
$5.89M
수익:
$2.00M
순이익/손실:
$-50.62M
주가수익비율:
-0.0849
EPS:
-41.8255
순현금흐름:
$-37.11M
1주 성능:
-2.74%
1개월 성능:
-16.86%
6개월 성능:
-90.93%
1년 성능:
-81.79%
1일 변동 폭
$3.34
$3.6099
1주일 범위
$3.34
$3.99
52주 변동 폭
$3.12
$71.50
바이오아틀라 Stock (BCAB) Company Profile
명칭
Bioatla Inc
전화
858-558-0708
주소
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
3.55 | 6.01M | 2.00M | -50.62M | -37.11M | -41.83 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
바이오아틀라 Stock (BCAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-08-13 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 개시 | JMP Securities | Mkt Outperform |
| 2022-05-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-06-28 | 개시 | ROTH Capital | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | BTIG Research | Buy |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | JP Morgan | Overweight |
| 2021-01-11 | 개시 | Jefferies | Buy |
모두보기
바이오아틀라 주식(BCAB)의 최신 뉴스
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEPS Consistency Score - newsline.com
BCAB Q4 2025 Earnings: Narrower Loss Surprises, Shares RiseLow Estimate Range - newsline.com
BioAtla Inc. (BCAB) Slips 2.5% as Shares Test Key Support ZoneBearish Pattern Stocks - newsline.com
BioAtla (BCAB) Slips 4.58% as Stock Nears Critical Support LevelTotal Put Call - newsline.com
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Offers Partial Offset Amid Stock DeclineAnalyst Consensus Shift - newsline.com
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline ProgressROA Comparison - newsline.com
BioAtla (NASDAQ: BCAB) CFO logs non-sale share withholdings for RSU taxes - Stock Titan
BioAtla (BCAB) CMO has 494 shares withheld to cover RSU taxes - Stock Titan
BioAtla (NASDAQ: BCAB) CEO reports routine tax-share withholdings after RSU vesting - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineMargin Guidance - newsline.com
BioAtla (NASDAQ: BCAB) schedules 2026 virtual meeting and pay vote - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Driven by Operational DisciplineEarnings Whisper Number - newsline.com
BioAtla Inc. (BCAB) Slips Nearly 3% as Biotech Sector Faces HeadwindsProfitability Factor - The Legal Advocate
BCAB Q4 2025 Earnings: EPS Surprise and Pipeline Focus Drive Positive SentimentEarnings Outlook Update - newsline.com
BioAtla Inc. (BCAB) Edges Higher as Stock Tests Key Resistance Near $3.95Schiff Line - The Legal Advocate
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentEarnings Beat Streak - newsline.com
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BioAtla (BCAB) Q4 2025 Earnings: EPS $-8.00 Beats EstimatesStrong Earnings Momentum - The Legal Advocate
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Sahm
Context Therapeutics Secures Full Rights to CT-202 from BioAtla with License Buyout, Phase 1 Trial Planned for Q3 2026 - Minichart
Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal - Moomoo
Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free - TradingView
Context Therapeutics enters into license agreement amendment with BioAtla for CT-202 - marketscreener.com
Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license - Stock Titan
The real story behind BioAtla BCAB valuation 333 20260507Margin Improvement Report - newsline.com
BioAtla (BCAB) slashes R&D, flags going-concern risk amid cash crunch - Stock Titan
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Number of shareholders of BioAtla, Inc. – NASDAQ:BCAB - TradingView
BioAtla (BCAB) Stock Analysis: +2.61% Gain — What to Watch 2026-05-14Continuation Pattern - newser.com
BCAB Q1'26 Earnings: EPS estimate is (10.00) USD - TradingView
TradingKey - TradingKey
The real story behind BioAtla (BCAB) valuation (-3.33%) 2026-05-07Quote Data - Newser
BCAB BioAtla delivers narrower than expected Q4 2025 loss, shares gain nearly two percent today.Social Trade Signals - newser.com
Why is BioAtla (BCAB) stock gaining attention recently | Q4 2025: Better Than ExpectedMarket Hype Signals - Newser
BioAtla, Inc. Executive Compensation, Governance, and Board Diversity Overview 2025 - Minichart
Executive pay, board and share data detailed in BioAtla (NASDAQ: BCAB) 10-K/A - Stock Titan
Is BioAtla (BCAB) stock reacting to key levels | Q4 2025: Earnings Beat EstimatesGeographic Revenue Trends - The Legal Advocate
BioAtla to implement 50-for-1 share consolidation - MSN
BCAB Stock Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Highs Report: What is the dividend yield of BioAtla IncPortfolio Performance Report & Verified Technical Signals - baoquankhu1.vn
BCAB Q4 2025 Earnings: BioAtla Inc. EPS Beats Estimates With No RevenueCFO Commentary Report - The Legal Advocate
BCAB Stock Analysis: BioAtla Inc. Biotech Drops 3.12% to $0.13 Key Takeaways - newsline.com
BioAtla Announces 1-for-50 Reverse Stock Split Merger - TipRanks
[8-K] BioAtla, Inc. Reports Material Event - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Sahm
BioAtla To Carry Out 1-for-50 Reverse Stock Split On April 6th, 2026 - Moomoo
BCAB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BioAtla announces 50-for-1 reverse stock split effective April 6 - Investing.com Australia
BioAtla announces 50-for-1 reverse stock split effective April 6 By Investing.com - Investing.com South Africa
바이오아틀라 (BCAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):